MyFinsight
Home
About
Contact
ikt: the income statement
Download
Download image
Net loss
-$11,930,280
Interest income
$838,093
Loss from operations
-$12,768,373
Total costs and
expenses
$12,768,373
Change in fair value
contingent consideration
$492,827
Selling, general and
administrative
$5,611,503
Research and development
$7,649,697
Back
Back
Income Statement
source: myfinsight.com
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)